Newsletter Tool

Editor’s note: The Fierce PM Tracker will be on a publishing break until Jan. 4. Check with Fierce Pharma, Fierce Biotech and Fierce Healthcare for the biggest headlines in the meantime. Happy holidays!

Today's Rundown

Pfizer's megablockbuster-to-be COVID pill Paxlovid scores FDA nod
2022 forecast: We wish we had better news for biotech dealmaking, but omicron is coming anyway
2022 forecast: Will biopharma's offices ever go back to 'normal'? Sanofi, Novartis and more chime in
2022 forecast: AR, VR poised to send medtech into the next dimension
Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators
2022 forecast: Competition in retail healthcare will heat up. Here's what to expect from Amazon, CVS and Walgreens
2022 forecast: Cell, gene therapy makers push past regulatory, payer hurdles to set up high hopes for next year
2022 forecast: Talent war in life sciences, salary inflation in C-suite builds to 'negative feedback loop'
Microsoft’s $19.7B Nuance purchase secures EU sign-off after antitrust investigation
2022 forecast: 5 trends that will make or break healthcare's labor shortages
Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree
Verily COO tacks on president title as CEO steps back from day-to-day duties
2022 forecast: Blood test breakthroughs set to move the needle in Alzheimer's, Parkinson's research
13.6M have signed up for coverage on ACA exchanges during open enrollment so far: CMS

Featured Story

Pfizer's megablockbuster-to-be COVID pill Paxlovid scores FDA nod

By Kevin Dunleavy

The FDA sanctioned Pfizer’s Paxlovid for emergency use. The drug is a highly anticipated oral medicine for recently infected individuals who are at a high risk of progressing to a severe form of the disease. For Pfizer, the authorization will bring another massive pandemic windfall.

2022 forecast: We wish we had better news for biotech dealmaking, but omicron is coming anyway

By Annalee Armstrong

We thought we’d finally get to see what a post-pandemic world looked like in 2022, but thanks to omicron, it seems we’re in for another round of virtual dealmaking and more.

2022 forecast: Will biopharma's offices ever go back to 'normal'? Sanofi, Novartis and more chime in

By Eric Sagonowsky

Through much of 2021, it seemed as if COVID-19 vaccines were enabling many countries to gently ease back into normalcy. Those hopes hit a rude awakening late in the year when the omicron variant emerged, and now industry leaders are forced—again—to quickly adapt.

2022 forecast: AR, VR poised to send medtech into the next dimension

By Andrea Park

A recent market research report estimated that between 2021 and 2026, the market for virtual reality in healthcare will grow by nearly 35% annually, swelling the market to more than $40 billion.

Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators

By Angus Liu

Biogen and Eisai’s attempt to expand controversial Alzheimer’s disease drug Aduhelm has hit a snag in another large market.

2022 forecast: Competition in retail healthcare will heat up. Here's what to expect from Amazon, CVS and Walgreens

By Rebecca Torrence

Walmart, CVS, Walgreens and Amazon have placed huge bets on healthcare this year. In 2022, industry experts anticipate that retailers will ramp up their investments in key technologies and tackle issues like social determinants of health and data sharing.

2022 forecast: Cell, gene therapy makers push past regulatory, payer hurdles to set up high hopes for next year

By Arlene Weintraub

Novartis, Bristol Myers Squibb and Gilead are among the companies expected to bring in high revenues from their cell and gene therapies in 2022. And the late-stage pipeline could produce several more cancer CAR-Ts and gene therapies to treat a range of diseases.

2022 forecast: Talent war in life sciences, salary inflation in C-suite builds to 'negative feedback loop'

By Kyle LaHucik

Biopharmas are not immune to the "Great Resignation" spurred by the pandemic, and drug developers will have to create new formulations to attract and retain talent, or at least improve current hiring practices, to stave off mass quitting in 2022.

Microsoft’s $19.7B Nuance purchase secures EU sign-off after antitrust investigation

By Andrea Park

One antitrust probe down, one more to go for Microsoft and its $19.7 billion bid to buy Nuance Communications.

2022 forecast: 5 trends that will make or break healthcare's labor shortages

By Dave Muoio

Analysts and stakeholders highlight five industry trends that will make or break healthcare’s labor shortage in the months and years to come.

Novartis inks $800M upfront buyout of Gyroscope to continue eye disease gene therapy M&A spree

By Nick Paul Taylor

Gyroscope Therapeutics has been spun this way and that in 2021, going from a $148 million raise to a failed IPO to a $40 million investment from Sanofi in quick succession. But Novartis has ensured the gene therapy startup has ended the year at the top of its arc by inking a $1.5 billion buyout.

Verily COO tacks on president title as CEO steps back from day-to-day duties

By Andrea Park

Stephen Gillett’s annual evaluation must have gone well: After just one year as chief operating officer at Verily, he’s been promoted to take on the role of president, too.

2022 forecast: Blood test breakthroughs set to move the needle in Alzheimer's, Parkinson's research

By Conor Hale

As is the case with nearly any biomedical endeavor, the inability to easily peek into the body’s inner workings severely stymies research. While progress has been made in cancer and other diseases, the brain has proven to be a tough nut to crack. That may be changing soon, with the advent of new blood diagnostics.

13.6M have signed up for coverage on ACA exchanges during open enrollment so far: CMS

By Paige Minemyer

A record 13.6 million people have signed up for coverage on the Affordable Care Act's exchanges, according to new data from CMS.

PM Tracker

Featured Story

Top Stories